Triple-negative breast cancer is a type of breast cancer that is ER & PR negative, lacks over expression of HER2. It accounts for 10 to 20% of breast cancers.
New research discusses fresh progress into the understanding, mechanisms, and therapeutic strategies to overcome triple negative breast cancer (TNBC).
Triple Negative Breast Cancer: New Findings
“Technological advancements such as //genomics and epigenomics have provided us with vast insight about the complexity of breast cancer." "However, one thing has remained the same, the need for the evaluation of three markers. These three markers; the expression of estrogen, progesterone, and HER2, are all molecular targets for treatment regimens, and are relied on by clinicians."What is Triple-Negative Breast Cancer?
Triple-negative breast cancer is a type of breast cancer that is ER negative, PR negative and lacks over expression of HER2. The cancer accounts for 10 to 20% of invasive breast cancers and has a poor prognosis or outcome. ER stands for estrogen receptors. Breast cancer cells that have estrogen receptors are sensitive to estrogen, the female hormone, which promotes the growth of the cancer.‘Tumor microenvironment (TME) was found to play a key role to develop and control triple negative breast cancer progression. ’
"Chemotherapy is the staple treatment for TNBC patients. However, they lack the expression of three key therapeutic markers. The lack of therapeutic markers leads to poorer outcomes in TNBC.” Source-Newswise